| Code | CSB-RA013481MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to APNmAb-005, targeting microtubule-associated protein tau (MAPT). MAPT plays a critical role in stabilizing neuronal microtubules and maintaining axonal transport in the central nervous system. Under pathological conditions, MAPT undergoes abnormal hyperphosphorylation and aggregation, forming neurofibrillary tangles that are hallmark features of Alzheimer's disease and other tauopathies, including frontotemporal dementia, progressive supranuclear palsy, and chronic traumatic encephalopathy. Dysregulated tau protein contributes to neurodegeneration through disruption of microtubule dynamics and synaptic dysfunction.
APNmAb-005 is a well-characterized reference antibody used in neurodegenerative disease research. This biosimilar provides researchers with a reliable tool for investigating tau protein expression, localization, and pathological modifications in various experimental models. The antibody supports studies examining tau biology, protein-protein interactions, and mechanisms underlying tau-mediated neurodegeneration, making it valuable for advancing understanding of tauopathies and potential therapeutic interventions.
There are currently no reviews for this product.